FDA approves J&J's Symtuza for HIV-1 infection in adults

FDA approved Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in adults who have not previously received antiretroviral therapy (ART) or who have HIV-1 RNA levels of less than 50 copies/mL on a stable antiretroviral regimen for at least six months and have no known substitutions associated with resistance to darunavir or tenofovir.

Last year, the European Commission approved Symtuza to treat HIV-1 infection in patients ages 12 and older with a body weight of at least 40 kg...